3-ethyl-1,1-dioxo-5-phenyl-3-propyl-4,5-dihydro-2H-1lambda6,4-benzothiazepin-8-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫氮卓类
• 英文名称: 3-ethyl-1,1-dioxo-5-phenyl-3-propyl-4,5-dihydro-2H-1lambda6,4-benzothiazepin-8-ol
• 英文别名: 3-ethyl-1,1-dioxo-5-phenyl-3-propyl-4,5-dihydro-2H-1λ6,4-benzothiazepin-8-ol
• 化学式: C₂₀H₂₅NO₃S
• 分子量: 359.5
• InChiKey: AFTMDWCXTSKNOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• US20140271734A1
  申请人：——

  公开号：US20140271734A1

  公开（公告）日：2014-09-18
• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
  申请人：Lumena Pharmaceuticals LLC

  公开号：US20200069715A1

  公开（公告）日：2020-03-05

  Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
• METHODS FOR TREATING CHOLESTASIS
  申请人：MIRUM PHARMACEUTICALS, INC.

  公开号：US20220160726A1

  公开（公告）日：2022-05-26

  Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day.